Polycythemia Vera Clinical Trials

22 recruiting

Polycythemia Vera Trials at a Glance

36 actively recruiting trials for polycythemia vera are listed on ClinicalTrialsFinder across 6 cities in 33 countries. The largest study group is Phase 2 with 14 trials, with the heaviest enrollment activity in New York, Seattle, and Columbus. Lead sponsors running polycythemia vera studies include FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS, Disc Medicine, Inc, and Icahn School of Medicine at Mount Sinai.

Browse polycythemia vera trials by phase

Treatments under study

About Polycythemia Vera Clinical Trials

Looking for clinical trials for Polycythemia Vera? There are currently 22 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Polycythemia Vera trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Polycythemia Vera clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 36 trials

Recruiting
Phase 1Phase 2

Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia

Myelodysplastic SyndromesMyelofibrosisAnemia+4 more
Disc Medicine, Inc150 enrolled24 locationsNCT05320198
Recruiting
Phase 1

A Phase 1 Study of PRT12396 in Participants With Select Myeloproliferative Neoplasms

Myelofibrosis (MF)Polycythemia Vera (PV)Myeloproliferative Neoplasms (MPNs)
Prelude Therapeutics100 enrolled1 locationNCT07469891
Recruiting
Phase 2

A Randomized Study of ASTX727 With or Without Iadademstat in Advanced Myeloproliferative Neoplasms (MPNs)

Myelodysplastic/Myeloproliferative NeoplasmPolycythemia VeraPrimary Myelofibrosis+5 more
National Cancer Institute (NCI)62 enrolled30 locationsNCT06661915
Recruiting
Phase 3

MITHRIDATE: Ruxolitinib Versus Hydroxycarbamide or Interferon as First Line Therapy in High Risk Polycythemia Vera

Polycythemia Vera
University of Birmingham586 enrolled47 locationsNCT04116502
Recruiting
Phase 2

Study of Momelotinib in Combination With Luspatercept in Participants With Transfusion Dependent Myelofibrosis

Primary MyelofibrosisMyelofibrosis; Primary Myelofibrosis; Post-polycythemia Vera Myelofibrosis; Post-essential Thrombocythemia Myelofibrosis
GlaxoSmithKline68 enrolled33 locationsNCT06517875
Recruiting
Phase 3

A Study to Evaluate Safety and Efficacy of Bomedemstat (MK-3543-017)

MyelofibrosisPolycythemia VeraPrimary Myelofibrosis+3 more
Merck Sharp & Dohme LLC400 enrolled21 locationsNCT06351631
Recruiting

Registry Platform Myelofibrosis and Anemia

MyelofibrosisAnemiaPrimary Myelofibrosis+4 more
iOMEDICO AG200 enrolled1 locationNCT06976918
Recruiting
Phase 3

Study on Efficacy and Safety of Givinostat Versus Hydroxyurea in Patients With Polycythemia Vera

Polycythemia Vera
Italfarmaco220 enrolled90 locationsNCT06093672
Recruiting
Phase 2

Curcumin to Improve Inflammation and Symptoms in Patients With Clonal Cytopenia of Undetermined Significance, Low Risk Myelodysplastic Syndrome, and Myeloproliferative Neoplasms

Myelodysplastic SyndromeMyelofibrosisPolycythemia Vera+2 more
University of Southern California30 enrolled2 locationsNCT06063486
Recruiting
Phase 3

AVAJAK: Apixaban/Rivaroxaban Versus Aspirin for Primary Prevention of Thrombo-embolic Complications in JAK2V617F-positive Myeloproliferative Neoplasms

Polycythemia VeraEssential ThrombocythemiaPrefibrotic/Early Primary Myelofibrosis+1 more
University Hospital, Brest1,308 enrolled42 locationsNCT05198960
Recruiting
Phase 2

Study of Canakinumab in Patients With Myelofibrosis

Primary MyelofibrosisPost-essential Thrombocythemia MyelofibrosisET-MF+2 more
John Mascarenhas14 enrolled8 locationsNCT05467800
Recruiting
Phase 2

Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms

Acute Myeloid LeukemiaMyelodysplastic SyndromeMyeloproliferative Neoplasm+6 more
University of Washington25 enrolled1 locationNCT04282187
Recruiting
Phase 1Phase 2

An Optimal Dose Finding Study of N-Acetylcysteine in Patients With Myeloproliferative Neoplasms

MyelofibrosisMyeloproliferative NeoplasmPolycythemia Vera+2 more
University of California, Irvine27 enrolled2 locationsNCT05123365
Recruiting
Phase 2

A Phase 2, Open-Label Study of DISC-3405 in Participants With Polycythemia Vera (PV)

Polycythemia Vera (PV)
Disc Medicine, Inc60 enrolled14 locationsNCT06985147
Recruiting
Phase 2

Phase IIa Study on Flonoltinib Maleate Tablets in the Treatment of Patients With Polycythemia Vera

Polycythemia Vera (PV)
Chengdu Zenitar Biomedical Technology Co., Ltd60 enrolled1 locationNCT07232290
Recruiting
Phase 1Phase 2

Open Label Phase 1/2 Study of Tasquinimod in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF), or Post-Essential Thrombocytosis Myelofibrosis (Post-ET MF)

Primary MyelofibrosisPost-polycythemia Vera MyelofibrosisPost-Essential Thrombocytosis Myelofibrosis
M.D. Anderson Cancer Center33 enrolled1 locationNCT06327100
Recruiting
Phase 3

A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis

Primary MyelofibrosisPost-polycythemia Vera MyelofibrosisPost-essential Thrombocythemia Myelofibrosis
Swedish Orphan Biovitrum399 enrolled207 locationsNCT03165734
Recruiting

MPN PROGRESSion Registry: Observational Study Tracking Symptoms, Treatments, and Disease Progression in People With Myeloproliferative Neoplasms (MPNs)

Polycythemia VeraET (Essential Thrombocythemia)Polycythemia Vera (PV)
MPN Research Foundation5,000 enrolled2 locationsNCT07362225
Recruiting

Ropeginterferon Alfa-2b in Patients With Polycythemia Vera (PV) Without Symptomatic Splenomegaly

Polycythemia Vera
iOMEDICO AG200 enrolled1 locationNCT06743035
Recruiting
Phase 2

Ruxolitinib in Thrombocythemia and Polycythemia Vera

Polycythemia VeraEssential Thrombocythemia
Massachusetts General Hospital60 enrolled4 locationsNCT04644211